Jeff Augen, currently a private investor and writer, has spent over a decade building a unique intellectual property portfolio of databases, algorithms, and associated software for technical analysis of derivatives prices. This work has been the subject of six books from Pearson Education (Financial Times Press): The Volatility Edge in Options Trading, The Option Trader’s Workbook, Trading Options at Expiration, Day Trading Options, Microsoft Excel for Stock and Option Traders, Trading Realities, and Options Trading Strategies.

Augen has a 25 year history in information technology. As co-founding executive of IBM’s Life Sciences Computing business, he defined a growth strategy that resulted in $1.2 billion of new revenue while managing a $400 million portfolio of venture capital investments in life sciences computing and medicine. During this time frame he also worked with the Mayo Clinic to develop a comprehensive clinical database system that combined new search and retrieval technologies along with clinical, demographic, and genomic markers. The project, co-funded by IBM and the Mayo Clinic, generated more than 40 patents during its first year.

From 2002 to 2005, Augen was President and CEO of TurboWorx Inc., a technical computing software company launched at Yale University.

During the past several years he has been an invited guest speaker at more than 50 industry events, an author of more than 150 articles, book chapters, and editorials, a member of 3 editorial boards, a weekly columnist for Stocks, Futures, and Options magazine, and the author of a graduate-level textbook, Bioinformatics in the Post-Genomic Era (Addison-Wesley 2005).

Previous steps in his career included a variety of business and technical roles including Chief Technologist for EDS’ Travel and Transportation Division.

Augen has undergraduate and graduate degrees in biochemistry from Rice University and the University of Texas Graduate School of Biomedical Sciences.